TailorDose™ **Short presentation: TailorDose® - A novel tool within Personalized Cancer Medicine**

Adduct Analys

Comment [PR1]: Så här brukar man generellt lägga upp sin pitch för sin affärside. För framtiden kan det vara värt att göra en 2 sidig pitch enligt nedan:
Problem
Affärside
Marknad
Affärsplan

TailorDose® is a project that was started in 2012 at the Karolinska Institute in Solna Stockholm. The project has been supported by the company Adduct Analys AB who owns IP and trademarks for the technology and BIO-X in Uppsala (BIO-X award 2011) and other grant providers.

The TailorDose® approach is based on a patented method, suitable for determination of the active dose of cytostatic drugs with cyclophosphamide being the first out. The aim is to customize "Tailor" the chemotherapy for each individual patient.

Today, dosing of cytostatic drugs are based on the patient's body surface area (mg/m^2 BSA) and it is well known that this estimate leads to suboptimal dosing of large proportion of patients (drug dependent often over 50 %). Our own data from a clinical study involving 150 patients receiving cyclophosphamide indicate that 22 % of the subjects are given a dose that is too low (affecting the efficacy of the treatment) and 17 % are given a dose which is too high (leading to higher risk of severe adverse side effects, often expressed late in the therapy). One single blood sample, taken at the routine control, a few days after the very first dose, is sufficient to obtain an exact dose measure to "TailorDose®" the therapy.

The market for such a product is huge, only in Sweden approximately 4500 patients are treated with cyclophosphamide each year. The product is currently being CE-marked and key opinion leaders such as prof. Jonas Bergh are directly involved in research to validate clinical benefits.

Another interesting opportunity for Big pharma companies would be to use TailorDose® as a tool to access more clinical info in clinical trials, also closed trials, and sold as companion diagnostics for products already on market. These three opportunities should be of high interest as the intra-individual variation of AUC-dose can be as very high, i.e., factor 15 for Imbruvica®. Benefits:

(I) Patients being wrongly dosed can be eliminated by reanalyzing samples from already closed trials, the statistics can be improved, optimal AUC level can be identified.

(II) The number of patients, when being actively dose adjusted with TailorDose®, can be much smaller than today to demonstrate the clinical value, especially valuable at late stages in clinical trials.

(III) The benefits by using the technology as a companion diagnostics will result in higher efficacy and higher safety. Patients will live longer and stay healthier. Highly valuable for the whole health care system, for society at large, for pharma companies (longer sales periods per patient to a higher price) and especially for the patient and near relatives at both the private and professional level.

(IV) Possibility to extend patent life.

For additional information, please contact:

Per Rydberg, PhD. Researcher and principal investigator for the TailorDose® approach at Karolinska Institute, dept of Oncology-Pathology, Solna Sweden. Rydberg is also founder, CEO and majority shareholder of Adduct Analys AB (org nr 556666-8421).
Phone: +4670 747 13 46, e-mail: per.rydberg@ki.se